Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Charité University Medicine Berlin

Status and phase: Unknown; Phase 3

Conditions: Renal Cell Carcinoma

Treatments: Other: Endurance exercise

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00869011

SUIR8687

Details and patient eligibility

About

In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.

Enrollment: 70 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 to 75 years
• Understanding of written German
• Treatment with Sunitinib
• Ability to walk

Exclusion criteria

• Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise
• BMI < 18 or > 30

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

70 participants in 2 patient groups

1

Experimental group

Description:

Exercise

Treatment:

Other: Endurance exercise

2

No Intervention group

Description:

No structured exercise program